Mexico hopes to receive from Argentina the active ingredient necessary for the development of doses of the vaccine against Covid-19 developed by the British laboratory AstraZeneca and the University of Oxford, announced Monday a member of the Mexican government.
Read also: Covid-19: unanswered questions about the effectiveness of AstraZeneca's vaccine formula
This Wednesday, we are pleased to receive the first of these bulk shipments, for about a million doses,
" Under Secretary of Health Hugo Lopez-Gatell said at a press conference.
This quantity is lower than that mentioned shortly before on Twitter by the Mexican Minister of Foreign Affairs Marcelo Ebrard, who had spoken of a shipment allowing the development of six million doses.
Thanks to this shipment, the finalization in Mexico of this vaccine will be possible, assured Marcelo Ebrard.
The Mexican health regulator, Cofepris, on January 4 authorized the use of this vaccine, which should be available from March, depending on the production capacities of the manufacturers.
” is produced in Argentina by the bio-pharmacy firm mAbxience before being shipped to Mexico where the vaccine will be produced by the Liomont laboratory.
The two laboratories will be able to produce around 250 million doses to meet demand in Latin America, according to the Mexican government.
Read also: Covid-19: are rich countries monopolizing vaccines?
Mexico has already placed an order with AstraZeneca to acquire 77.4 million doses.
It has also made deals to acquire other vaccines, including the Russian Sputnik V. These preparations to develop the Astrazeneca / Oxford vaccine take place as the Mexican government announced a reduction in the supply of Pfizer-BioNTech vaccines to which it had been entitled, complying with the UN's request to rich countries to share with the poorest countries the additional doses they had purchased.